5 trends tracked about this subject — the full history, oldest to newest below.
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Inhibrx claims a first-of-its-kind win for a long-sought immunotherapy target with new clinical data.
Summit Therapeutics and Akeso report that their cancer drug ivonescimab has met overall survival goals in a Phase 3 lung cancer trial.